| Q34225229 | Altered NEP2 expression and activity in mild cognitive impairment and Alzheimer's disease |
| Q28477836 | Alzheimer's disease and non-demented high pathology control nonagenarians: comparing and contrasting the biochemistry of cognitively successful aging |
| Q35917682 | BACE2 expression increases in human neurodegenerative disease |
| Q36659692 | Biomarkers for oxidative stress status of DNA, lipids, and proteins in vitro and in vivo cancer research |
| Q26771852 | Cerebrovascular disease in ageing and Alzheimer's disease |
| Q34665155 | Decreased Neprilysin and Pulmonary Vascular Remodeling in Chronic Obstructive Pulmonary Disease |
| Q27022552 | Diabetes and Alzheimer disease, two overlapping pathologies with the same background: oxidative stress |
| Q39987132 | Down-regulation of insulin-degrading enzyme by presenilin 1 V97L mutant potentially underlies increased levels of amyloid beta 42. |
| Q33642530 | Effects of 4-hydroxy-nonenal and Amyloid-beta on expression and activity of endothelin converting enzyme and insulin degrading enzyme in SH-SY5Y cells |
| Q37219722 | Effects of HNE-modification induced by Abeta on neprilysin expression and activity in SH-SY5Y cells |
| Q46208530 | Experimental investigation of antibody-mediated clearance mechanisms of amyloid-beta in CNS of Tg-SwDI transgenic mice. |
| Q37319051 | Getting the iron out: phlebotomy for Alzheimer's disease? |
| Q42130528 | HIV-1 reduces Abeta-degrading enzymatic activities in primary human mononuclear phagocytes |
| Q36660696 | In vitro oxidative inactivation of human presequence protease (hPreP). |
| Q35500677 | Loss of neutral endopeptidase activity contributes to neutrophil activation and cardiac dysfunction during chronic hypomagnesemia: Protection by substance P receptor blockade |
| Q35687287 | Mechanisms of brain aging regulation by insulin: implications for neurodegeneration in late-onset Alzheimer's disease |
| Q38910551 | Mercury Reduces the Enzymatic Activity of Neprilysin in Differentiated SH-SY5Y Cells |
| Q33646882 | Metals and cholesterol: two sides of the same coin in Alzheimer's disease pathology |
| Q27652766 | Molecular Bases for the Recognition of Short Peptide Substrates and Cysteine-Directed Modifications of Human Insulin-Degrading Enzyme † |
| Q24657471 | Molecular basis for the thiol sensitivity of insulin-degrading enzyme |
| Q50932512 | Multiple functions of insulin-degrading enzyme: a metabolic crosslight? |
| Q34581928 | N-acetylcysteine prevents 4-hydroxynonenal- and amyloid-beta-induced modification and inactivation of neprilysin in SH-SY5Y cells |
| Q37408544 | Neprilysin and Aβ Clearance: Impact of the APP Intracellular Domain in NEP Regulation and Implications in Alzheimer's Disease |
| Q37150753 | Neprilysin null mice develop exaggerated pulmonary vascular remodeling in response to chronic hypoxia |
| Q26828757 | On the role of 4-hydroxynonenal in health and disease |
| Q92384162 | Oxidative inactivation of amyloid beta-degrading proteases by cholesterol-enhanced mitochondrial stress |
| Q38016899 | Proteolytic degradation of amyloid β-protein |
| Q34672360 | Proteolytically inactive insulin-degrading enzyme inhibits amyloid formation yielding non-neurotoxic aβ peptide aggregates |
| Q42366918 | Proteomic Characterization of Armillaria mellea Reveals Oxidative Stress Response Mechanisms and Altered Secondary Metabolism Profiles |
| Q34712680 | Redox regulation of insulin degradation by insulin-degrading enzyme |
| Q58842294 | Role of amyloid-β–metal interactions in Alzheimer’s disease |
| Q24317274 | Structure of substrate-free human insulin-degrading enzyme (IDE) and biophysical analysis of ATP-induced conformational switch of IDE |
| Q40782441 | Structure, function, and regulation of insulin-degrading enzyme |
| Q92008457 | Supraphysiologic-dose anabolic-androgenic steroid use: A risk factor for dementia? |
| Q38664408 | Targeting Insulin-Degrading Enzyme to Treat Type 2 Diabetes Mellitus |
| Q48459186 | Tat peptides inhibit neprilysin |
| Q50059412 | The antioxidant xanthorrhizol prevents amyloid-β-induced oxidative modification and inactivation of neprilysin |
| Q28574836 | The catalytic domain of insulin-degrading enzyme forms a denaturant-resistant complex with amyloid beta peptide: implications for Alzheimer disease pathogenesis |
| Q34657827 | The irreversible binding of amyloid peptide substrates to insulin-degrading enzyme: a biological perspective |
| Q35908404 | The mitochondria-targeted antioxidant MitoQ prevents loss of spatial memory retention and early neuropathology in a transgenic mouse model of Alzheimer's disease. |
| Q36812453 | Transcriptional regulation of insulin-degrading enzyme modulates mitochondrial amyloid β (Aβ) peptide catabolism and functionality. |
| Q41674220 | White matter hypoperfusion and damage in dementia: post-mortem assessment |
| Q21284467 | beta-Amyloid degradation and Alzheimer's disease |